These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19091853)

  • 1. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab.
    Lee AY; Raya AK; Kymes SM; Shiels A; Brantley MA
    Br J Ophthalmol; 2009 May; 93(5):610-3. PubMed ID: 19091853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab.
    Brantley MA; Fang AM; King JM; Tewari A; Kymes SM; Shiels A
    Ophthalmology; 2007 Dec; 114(12):2168-73. PubMed ID: 18054635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration.
    Nischler C; Oberkofler H; Ortner C; Paikl D; Riha W; Lang N; Patsch W; Egger SF
    Acta Ophthalmol; 2011 Jun; 89(4):e344-9. PubMed ID: 21232084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic influence of LOC387715/HTRA1 on the efficacy of bevacizumab treatment for age-related macular degeneration in a Korean population.
    Kang HK; Yoon MH; Lee DH; Chin HS
    Korean J Ophthalmol; 2012 Dec; 26(6):414-22. PubMed ID: 23204795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.
    Smailhodzic D; Muether PS; Chen J; Kwestro A; Zhang AY; Omar A; Van de Ven JP; Keunen JE; Kirchhof B; Hoyng CB; Klevering BJ; Koenekoop RK; Fauser S; den Hollander AI
    Ophthalmology; 2012 Nov; 119(11):2304-11. PubMed ID: 22840423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the CFH Y402H Polymorphism with the 1-Year Response of Exudative AMD to Intravitreal Anti-VEGF Treatment in the Brazilian Population.
    Medina FMC; Motta AALD; Takahashi WY; Carricondo PC; Motta MMDS; Melo MB; Vasconcellos JPC
    Ophthalmic Res; 2019; 61(3):168-173. PubMed ID: 28641277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of CFH polymorphisms on the response to the treatment of age-related macular degeneration (AMD) with intravitreal ranibizumab.
    Dikmetas O; Kadayıfcılar S; Eldem B
    Mol Vis; 2013; 19():2571-8. PubMed ID: 24367156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (nAMD).
    Mohamad NA; Ramachandran V; Ismail P; Mohd Isa H; Chan YM; Ngah NF; Md Bakri N; Ching SM; Hoo FK; Wan Sulaiman WA; Inche Mat LN; Hazmi Mohamed M
    Bosn J Basic Med Sci; 2018 Aug; 18(3):260-267. PubMed ID: 29579408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Association between Y402H, E318D and R102G polymorphisms of complement proteins genes and the response to intravitreal anti-VEGF treatment in patients with neovascular age-related macular degeneration].
    Kubicka-Trząska A; Karska-Basta I; Kobylarz J; Dziedzina S; Sanak M; Romanowska-Dixon B
    Klin Oczna; 2016; 118(2):114-21. PubMed ID: 29912491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).
    Hagstrom SA; Ying GS; Pauer GJT; Sturgill-Short GM; Huang J; Callanan DG; Kim IK; Klein ML; Maguire MG; Martin DF;
    Ophthalmology; 2013 Mar; 120(3):593-599. PubMed ID: 23337555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined effects of genetic and non-genetic risk factors affect response to ranibizumab in exudative age-related macular degeneration.
    Piermarocchi S; Miotto S; Colavito D; Leon A; Segato T
    Acta Ophthalmol; 2015 Sep; 93(6):e451-7. PubMed ID: 25402348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population.
    Chang W; Noh DH; Sagong M; Kim IT
    Mol Vis; 2013; 19():702-9. PubMed ID: 23559864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Y402H polymorphism in complement factor H and age-related macular degeneration in the Tunisian population.
    Habibi I; Sfar I; Kort F; Aounallah-Skhiri H; Chebil A; Chouchene I; Bouraoui R; Limaiem R; Largheche L; Jendoubi-Ayed S; Makhlouf M; Ben Abdallah T; Ayed K; El Matri L; Gorgi Y
    Ophthalmic Res; 2013; 49(4):177-84. PubMed ID: 23306536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study (an American Ophthalmological Society thesis).
    Francis PJ
    Trans Am Ophthalmol Soc; 2011 Dec; 109():115-56. PubMed ID: 22253485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration.
    Teper SJ; Nowinska A; Pilat J; Palucha A; Wylegala E
    Mol Vis; 2010 Dec; 16():2598-604. PubMed ID: 21151600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of the polymorphism Y402H in the CFH gene with response to anti-VEGF treatment in age-related macular degeneration: a systematic review and meta-analysis.
    Hong N; Shen Y; Yu CY; Wang SQ; Tong JP
    Acta Ophthalmol; 2016 Jun; 94(4):334-45. PubMed ID: 27151934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration.
    McKibbin M; Ali M; Bansal S; Baxter PD; West K; Williams G; Cassidy F; Inglehearn CF
    Br J Ophthalmol; 2012 Feb; 96(2):208-12. PubMed ID: 21558292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CFH Y402H polymorphism and response to intravitreal ranibizumab in Brazilian patients with neovascular age-related macular degeneration.
    Veloso CE; Almeida LN; Nehemy MB
    Rev Col Bras Cir; 2014; 41(6):386-92. PubMed ID: 25742403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
    Abedi F; Wickremasinghe S; Richardson AJ; Islam AF; Guymer RH; Baird PN
    Ophthalmology; 2013 Aug; 120(8):1641-8. PubMed ID: 23582991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age-related macular degeneration.
    Wegscheider BJ; Weger M; Renner W; Steinbrugger I; März W; Mossböck G; Temmel W; El-Shabrawi Y; Schmut O; Jahrbacher R; Haas A
    Ophthalmology; 2007 Apr; 114(4):738-42. PubMed ID: 17398321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.